Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OFIRMEV vs ZYDELIG
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.
Idelalisib is a selective inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ), blocking the PI3K/AKT signaling pathway, leading to reduced proliferation, survival, and migration of malignant B cells.
Management of mild to moderate pain,Management of moderate to severe pain with adjunctive opioid analgesics,Reduction of fever
Relapsed chronic lymphocytic leukemia (CLL) in combination with rituximab,Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies,Relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies
IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.
150 mg orally twice daily, taken with food.
Terminal elimination half-life is 2-3 hours in adults (2.5-3 hours in children). Clinically, dosing every 4-6 hours is needed to maintain therapeutic levels.
Terminal elimination half-life is 6.5 hours (range 4-10 hours) after oral administration, supporting twice-daily dosing.
Acetaminophen is primarily metabolized in the liver via conjugation with glucuronide (50-60%) and sulfate (20-30%). A minor amount is oxidized by cytochrome P450 (CYP2E1, CYP1A2, CYP3A4) to a toxic reactive metabolite (NAPQI), which is normally detoxified by glutathione. At toxic doses, glutathione is depleted, leading to NAPQI accumulation and hepatotoxicity.
Primarily metabolized by aldehyde oxidase (AO) and CYP3A4, with minor contributions from UGT1A4.
Primarily renal (85% as sulfate and glucuronide conjugates, 10% as unchanged drug). Less than 5% fecal/biliary.
Primarily hepatic metabolism, with 44% of dose excreted in feces (as metabolites) and 22% in urine (unchanged drug and metabolites).
10-25% bound to albumin at therapeutic concentrations.
84% bound to plasma proteins, primarily to albumin and alpha-1-acid glycoprotein.
0.8-1.0 L/kg. Indicates distribution into total body water.
Mean volume of distribution is 113 L (approximately 1.4 L/kg), indicating extensive tissue distribution.
100% (intravenous); not applicable for other routes as OFIRMEV is IV only.
Absolute oral bioavailability is 40% (range 30-50%) due to first-pass metabolism.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, extend dosing interval to every 8 hours; maximum daily dose 3000 mg.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). For severe renal impairment (Cr Cl <30 m L/min), not recommended due to lack of data.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce total daily dose by 50% (max 2000 mg/day). Child-Pugh Class C: Contraindicated or use with extreme caution; reduce dose to 50% of standard and extend interval to every 8 hours; maximum 2000 mg/day.
Child-Pugh Class A: No dose adjustment. Child-Pugh Class B: Reduce dose to 100 mg twice daily. Child-Pugh Class C: Not recommended.
Weight-based: <10 kg: 7.5 mg/kg/dose every 6 hours; 10-50 kg: 15 mg/kg/dose every 6 hours; >50 kg: 1000 mg every 6 hours or 650 mg every 4 hours. Maximum single dose: 15 mg/kg (up to 1000 mg); maximum daily dose: 75 mg/kg (up to 4000 mg).
Safety and efficacy not established for patients <18 years.
No specific dose adjustment; consider reduced renal function. For Cr Cl <30 m L/min, extend interval to every 8 hours. Maximum daily dose: 3000 mg in frail elderly or with comorbidities.
No specific dose adjustment recommended, but monitor for age-related renal and hepatic function changes.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.
WARNING: FATAL AND SERIOUS TOXICITIES: Hepatic, severe diarrhea/colitis, pneumonitis, and intestinal perforation. Fatal and/or serious hepatotoxicity occurred in 18% of patients. Fatal and/or serious diarrhea or colitis occurred in 14%. Fatal and/or serious pneumonitis occurred in 4%. Fatal and/or serious intestinal perforation occurred in <1%.
Risk of serious hepatotoxicity, especially with doses >4000 mg/day or in patients with underlying liver disease,Risk of severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis) – discontinue at first sign of rash,Risk of hypersensitivity reactions including anaphylaxis,Use caution in patients with severe hepatic impairment, active hepatic disease, or alcoholism,Avoid concurrent use of other acetaminophen-containing products
Hepatotoxicity: Monitor liver function tests,Severe diarrhea/colitis: Manage with supportive care and corticosteroids,Pneumonitis: Interrupt therapy and evaluate,Intestinal perforation: Discontinue if suspected,Infections: Monitor for opportunistic infections, including CMV,Neutropenia: Monitor blood counts,Embryofetal toxicity: Can cause fetal harm,Vaccinations: Avoid live vaccines during treatment
Known hypersensitivity to acetaminophen or any component of the formulation,Severe hepatic impairment or active liver disease (relative contraindication without black box)
History of severe hypersensitivity (e.g., anaphylaxis, Stevens-Johnson syndrome) to idelalisib or any excipient
No known food interactions. However, avoid excessive alcohol consumption as it may increase the risk of liver damage.
Avoid grapefruit and grapefruit juice (CYP3A4 inhibition increases idelalisib exposure). Take with food to reduce nausea and diarrhea.
Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dose use in third trimester may be associated with preterm birth or low birth weight. Avoid prolonged use above recommended doses.
Pregnancy Category D. First trimester: Risk of fetal malformations including neural tube defects and craniofacial anomalies based on animal studies showing embryo-fetal toxicity and teratogenicity. Second and third trimesters: Risk of fetal hematologic toxicity (leukopenia, neutropenia) and potential growth restriction. Counsel women of childbearing age to use effective contraception during treatment and for 1 month after last dose.
Acetaminophen is excreted in breast milk in low concentrations (M/P ratio approximately 0.9-1.0). Considered compatible with breastfeeding; peak milk levels occur 1-2 hours after maternal dosing. Use lowest effective dose for shortest duration.
No human data on presence in breast milk; risk of serious adverse reactions in breastfed infants (immunosuppression, neutropenia). M/P ratio not determined. Advise not to breastfeed during treatment and for 1 week after last dose.
No dose adjustment required during pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may lead to lower peak concentrations but standard dosing remains effective. Maximum single dose: 1 g; maximum daily dose: 4 g.
No dose adjustment studies in pregnant women. Due to increased volume of distribution and altered clearance in pregnancy, therapeutic drug monitoring is not established. Use minimum effective dose. If used during pregnancy, monitor for maternal neutropenia, infections, and adjust dose per standard ANC thresholds (hold if ANC < 500/mm³; resume at reduced dose when ANC > 1000/mm³).
OFIRMEV (acetaminophen) injection is an IV formulation of acetaminophen used for pain and fever management. It is a prodrug that requires no hepatic conversion, providing rapid onset of action. Monitor for hepatotoxicity; maximum daily dose is 4 grams in adults but lower in patients with hepatic impairment or malnutrition. Do not exceed 1 gram per dose. Hypotension and anaphylaxis have been reported. Not interchangeable with oral acetaminophen due to dose equivalency. Use with caution in patients with alcohol use disorder.
Monitor for hepatotoxicity (ALT/AST elevations), severe cutaneous reactions (Stevens-Johnson syndrome), and pneumonitis. Requires hepatic function monitoring every 2 weeks for first 2 months, then monthly. Contraindicated with CYP3A4 inducers or strong inhibitors due to metabolism via CYP3A4. Dose reduction needed for moderate hepatic impairment (Child-Pugh B).
OFIRMEV is given intravenously for pain or fever.,Do not take additional acetaminophen-containing medications while receiving OFIRMEV.,Report any signs of allergic reaction (rash, itching, swelling, trouble breathing).,Seek immediate medical attention if you experience severe abdominal pain, yellowing of skin or eyes, or dark urine.,Inform your healthcare provider about all medications you are taking, especially blood thinners.
Take with food to reduce gastrointestinal side effects.,Avoid grapefruit and grapefruit juice during treatment.,Report any signs of liver problems (jaundice, dark urine, abdominal pain) or skin reactions (rash, blisters) immediately.,Use effective contraception during and for at least 1 month after treatment.,Do not stop or change dose without consulting your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OFIRMEV vs ZYDELIG, answered by our medical review team.
OFIRMEV is a Non-opioid Analgesic that works by OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.. ZYDELIG is a PI3K Inhibitor Antineoplastic that works by Idelalisib is a selective inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ), blocking the PI3K/AKT signaling pathway, leading to reduced proliferation, survival, and migration of malignant B cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OFIRMEV and ZYDELIG depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OFIRMEV is: IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.. The standard adult dose of ZYDELIG is: 150 mg orally twice daily, taken with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OFIRMEV and ZYDELIG in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OFIRMEV is classified as Category C. Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dos. ZYDELIG is classified as Category C. Pregnancy Category D. First trimester: Risk of fetal malformations including neural tube defects and craniofacial anomalies based on animal studies showing embryo-fetal toxicity an. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.